Clinical Trial

A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis

Completed Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a, phase 1/2a trial, to assess the safety, tolerability, systemic exposure as well as preliminary efficacy following a single intra-articular injection of 3 dose levels of SYN321 in patients with symptomatic knee osteoarthritis (KOA).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-23; most recent amendment 2026-03-05.
Status change: Recruiting → Completed 2026-03-05
Status change: Not Yet Recruiting → Recruiting 2025-08-26
Trial Details
NCT Number NCT06989645
Lead Sponsor Synartro AB
Collaborators: CTC Clinical Trial Consultants AB
Conditions Osteoarthritis of Knee
Enrollment 35 participants
Start Date 2025-08-19
Primary Completion 2026-02-02 (estimated)
Study Completion 2026-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-06